Earnings release
Page 1
MAMPULAÇÃO viveo EARNINGS RELEASE 2Q26
Page 2
Earning Release 2Q26 e 1H26 ▪ 1 About Viveo An Example of Care Viveo operates as an integrated healthcare solutions platform, combining products and services across the entire healthcare value chain. Its business model connects different areas of operation, delivering agile, reliable, and innovative solutions to customers throughout Brazil. Founded in 1996, the Company is a leading provider in the manufacturing and distribution of medical supplies and pharmaceuticals for the healthcare sector, with nationwide presence and a comprehensive portfolio. With 100% Brazilian capital, Viveo operates 52 facilities, more than 100 thousand square meters of distribution centers strategically located across all regions of Brazil, and a workforce of more than 6 thousand direct employees. Its integrated operations reflect a strong specialization in care, guided by a vision that recognizes each life as unique, connecting the healthcare value chain to simplify access to healthcare throughout the country.
Page 3
Earning Release 2Q26 e 1H26 ▪ 2 São Paulo, August 11, 2026 – CM Hospitalar S.A. (“Viveo” or the “Company”) hereby announces its results for the second quarter (2Q26) and first half (1H26) of 2026. The following financial and operating information, except where otherwise stated, is presented on a consolidated basis a nd in accordance with the applicable corporate legislation. The figures are presented in thousands of Brazilian reais (R$ thousand), unless otherwise stated, and are compared to the second quarter (2Q25) and first half of 2025 (1H25). 2Q26/1H26 OPERATING HIGHLIGHTS 1 - Considers the same non-recurring items reported in EBITDA, as well as the amortization of acquisition-related fair value adjustments, net of a 34% tax rate. 2Q26 2Q25 Var. % 1H26 1H25 Var.% Net Revenue 2,910,169 2,815,509 3.4% 5,742,089 5,600,402 2.5% Gross Profit 483,917 422,451 14.5% 930,396 806,670 15.3% Gross Margin 16.6% 15.0% 1.6 p.p 16.2% 14.4% 1.8 p.p Adjusted EBITDA 216,684 177,850 21.8% 424,830 337,415 25.9% Adjusted EBITDA Margin 7.4% 6.3% 1.1 p.p 7.4% 6.0% 1.4 p.p Adjusted Net Income (Loss)¹ (21,265) (44,272) -52.0% (56,581) (65,157) -13.2% 2Q26 EARNINGS CONFERENCE CALL Held in Portuguese with simultaneous translation into English. Data: August 12,2026 Time: 10:00 a.m. BRT / 09:00 a.m. NYC Webcast: clique aqui Adjusted EBITDA of R$ 217 million in 2Q26, the highest quarterly result level since 3Q23 Gross Margin of 16.1% in 2Q26, the highest level since 2Q23 Cash Conversion Cycle of 53 days in 2Q26, a reduction of 4 days compared to 2Q25 Free Cash Flow generation of R$ 124.8 million in 2Q26, and R$ 170.3 million in 1H26 vs. R$ 124.6 million in 1H25 Leverage ratio of 3.73x in 2Q26, reinforcing the Company’s financial discipline 15.0% 14.5% 13.5% 13.3% 13.2% 13.2% 13.8% 14.6% 14.7% 14.3% 15.8% 16.1% 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 Gross Margin Ex-CMED 202 158 178 153 164 160 178 173 196 208 217 7.0% 5.3% 6.5% 5.2% 5.6% 5.7% 6.3% 6.1% 6.3% 7.4% 7.4% 0,0% 1,0% 2,0% 3,0% 4,0% 5,0% 6,0% 7,0% 8,0% - 100 200 300 400 500 600 700 800 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 Adjusted EBITDA vs. Adjusted EBITDA Margin Adjusted EBITDA Adjusted EBITDA Margin
Page 4
Earning Release 2Q26 e 1H26 ▪ 3 Message from Management The second quarter of 2026 reinforces the consistency of Viveo’s operational evolution and the Company’s ability to execute the priorities established for this new cycle. Despite a still challenging macroeconomic environment, marked by high interest rates and changes in healthcare industry dynamics, we maintained our trajectory of selective growth, profitability improvement and cash generation, with advances in operational efficiency and working capital management, while maintaining customer service levels as one of the Company’s priorities. Net Revenue reached R$ 2.9 billion in the quarter, an increase of 3.4% compared to the same period of the previous year, mainly supported by the performance of the Hospitals and Clinics business unit. This performance was achieved despite the lowest CMED p rice adjustment in the past 20 years and more challenging comparison bases in certain businesses, demonstrating the resilience of our operations and discipline in commercial execution. We continue to prioritize earnings quality. The evolution of Gross Profit, Adjusted EBITDA and margins reflects the continuity of initiatives implemented over the past quarters, including active portfolio and contract management, improved commercial negoti ations, synergy capture, and disciplined management of costs, expenses and capital employed. These advances also contributed to higher cash generation in the first half and the continued improvement in the Cash Conversion Cycle. We also advanced our operational excellence agenda, with initiatives focused on reviewing and standardizing processes, reducing waste and continuously improving service levels, including the adoption of the Lean Six Sigma methodology across different areas of the Company. This work strengthens our ability to identify opportunities, increase operational efficiency and sustain the gains achieved. In parallel with our operational evolution, we took important steps to strengthen Viveo’s capital structure. The extension of the debt maturity profile completed in June provided greater cash flow flexibility for the Company, preserving our execution capacity as we advance our deleveraging agenda, which remains a key priority for the Company. Subsequently, a capital increase of up to R$ 869.8 million was announced, with a minimum subscription of R$ 427.0 million secured through a commitment from investment vehicles managed by DNA Capital. In addition to contributing to the reduction of Net Debt and strengthening the balance sheet, this commitment represents an important demonstration of confidence from the Company’s reference shareholder in Viveo, its assets and its long-term value creation potential. The advances achieved during the quarter reinforce the Company we are building: a Viveo guided by consistency, execution and continuous improvement, with a stronger balance sheet, more efficient operations and high levels of customer service. We will conti nue to act with discipline and a clear sense of priorities, consolidating the results achieved and preparing the Company for sustainable and profitable growth. André Clark CEO
Page 5
Earning Release 2Q26 e 1H26 ▪ 4 Financial Indicators 1 - Margins calculated by dividing Adjusted EBITDA and Adjusted Net Income by Net Revenue. 2 - Considers the same non-recurring items reported in EBITDA, as well as the amortization of acquisition-related fair value adjustments, net of a 34% tax rate. 3 - EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization): operating performance measure in accordance with CVM Resolution No. 156/2022. Net Revenue Net Revenue totaled R$ 2,910.2 million in 2Q26, an increase of 3.4% compared to 2Q25 and 2.5% sequentially (vs. 1Q26). Performance mainly reflects the growth in Hospitals and Clinics, which offset declines across the other channels. The period was marked b y price normalization following the price increases implemented at the beginning of the year in Retail, the lowest medication price adjustment defined by CMED in the past 20 years, and a higher comparison base in Laboratories and Vaccines. In the latter, 2Q25 benefited from the seasonality of flu vaccination campaigns and the ramp-up of new vaccines, which at the time were concentrated in the private healthcare network. The result also reflects the continued active management of the customer and contract portfolio. Following a broader cycle of renegotiations in 2025, the initiatives carried out this year focused on more specific adjustments, contributing to an improved mi x toward a business base with a better balance between growth and profitability, as well as a reduction in the average contract term. In 1H26, Net Revenue totaled R$ 5,742.1 million, an increase of 2.5% compared to 1H25. Year-to- date, the growth in Hospitals and Clinics more than offset the effects of stronger comparison bases in Laboratories and Vaccines and Retail, as well as lower rev enue in Services, associated with the strategic reconfiguration of the compounding operation. Performance demonstrates the Company’s ability to sustain R$ thousand 2Q26 2Q25 Var.% 1H26 1H25 Var.% Net Revenue 2,910,169 2,815,509 3.4% 5,742,089 5,600,402 2.5% Cost of Goods and Services Sold (2,426,252) (2,393,058) 1.4% (4,811,693) (4,793,733) 0.4% Gross Profit 483,917 422,451 14.5% 930,396 806,670 15.3% Gross Margin 16.6% 15.0% 1.6 p.p 16.2% 1.4% 1.8 p.p Operating Expenses (347,968) (337,397) 3.1% (683,027) (649,565) 5.2% Financial Result (182,322) (157,674) 15.6% (355,261) (259,125) 37.1% Profit Before Income Tax and Social Contribution (46,373) (72,620) -36.1% (107,892) (102,020) 5.8% Income Tax and Social Contribution 11,721 1,262 828.8% 16,232 (28,271) N/A Net Income (Loss) (34,652) (71,358) -51.4% (91,660) (130,292) -29.7% Adjusted Net Income (Loss) (21,265) (44,272) -52.0% (56,581) (65,157) -13.2% Adjusted Net Margin¹˒² -0.7% -1.6% 0.8 p.p -1.0% -1.2% 0.2 p.p EBITDA3 223,155 165,605 34.8% 427,678 317,106 34.9% EBITDA Margin 7.7% 5.9% 1.8 p.p 7.4% 5.7% 1.8 p.p Adjusted EBITDA 216,684 177,850 21.8% 424,830 337,415 25.9% Adjusted EBITDA Margin¹ 7.4% 6.3% 1.1 p.p 7.4% 6.0% 1.4 p.p R$ thousand 2Q26 2Q25 Var.% 1H26 1H25 Var.% Hospitals and Clinics 2,150,115 1,940,375 10.8% 4,272,686 3,967,576 7.7% Laboratories and Vaccines 311,232 404,348 -23.0% 626,864 742,917 -15.6% Retail 254,095 254,537 -0.2% 458,297 476,350 -3.8% Services 194,728 216,250 -10.0% 384,242 413,559 -7.1% Total 2,910,169 2,815,509 3.4% 5,742,089 5,600,402 2.5%
Page 6
Earning Release 2Q26 e 1H26 ▪ 5 growth despite the lower contribution from price adjustments and the greater selectivity adopted across certain business areas. Hospitals and Clinics Net Revenue from Hospitals and Clinics reached R$ 2,150.1 million in 2Q26, an increase of 10.8% compared to 2Q25, accelerating from the 4.7% growth recorded in the previous quarter. Performance was mainly driven by volume growth in Pharmaceuticals and the evolution of contracts with key customers. The channel’s expansion, even amid a lower CMED price adjustment compared to the previous year, reinforces the Company’s commercial strength. The contract adjustments carried out throughout 2026 also supported the evolution of the mix, continuing the broader portfolio review process conducted in 2025. In 1H26, Net Revenue from the channel totaled R$ 4,272.7 million, an increase of 7.7% compared to 1H25, consolidating Hospitals and Clinics as the Company’s main growth driver during the period. Laboratories and Vaccines Net Revenue from Laboratories and Vaccines reached R$ 311.2 million in 2Q26, a decrease of 23.0% compared to 2Q25. Performance reflects the higher comparison base in Vaccines, which benefited in the prior period from vaccination campaigns and the ramp-up of new vaccines. In 2026, the inclusion of certain vaccines in the public healthcare network, which had previously been concentrated in the private network, shifted a significant portion of demand to this market. In Laboratories, revenue remained stable, despite occasional reagent unavailability in the Analytical segment. In 1H26, Net Revenue from the channel totaled R$ 626.9 million, a decrease of 15.6% compared to 1H25. Performance mainly reflected the change in the dynamics of the Vaccines market, with part of the demand shifting to the public channel, in addition to the occasional unavailability observed in the Analytical segment. Retail In Retail, Net Revenue reached R$ 254.1 million in 2Q26, remaining stable compared to 2Q25 ( - 0.2%). Following the price increases implemented at the beginning of the year, the period was marked by price normalization in the market and its effects on sales volumes. Nevertheless, the portfolio maintained a positive evolution in market share. Among the highlights, wound care products reinforced their category leadership, while bandages recorded gains in their overall share of results. In 1H26, Net Revenue from the channel totaled R$ 458.3 million, a decrease of 3.8% compared to 1H25. The cumulative performance mainly reflects the pressure on volumes observed following the price adjustments, with revenue improving throughout the second quarter. Services Net Revenue from Services reached R$ 194.8 million in 2Q26, a decrease of 10.0% compared to 2Q25. The year -over-year decline still reflects adjustments to the contracting model for compounding services, driven by the partial insourcing of these activities by large customers, in addition to lower demand for sterile solutions. In 2026, Insuma, the channel’s main operation, has been advancing in adapting its portfolio to this new dynamic, with a greater share of more profitable business lines. In this context, the sequential
Page 7
Earning Release 2Q26 e 1H26 ▪ 6 evolution in revenue — which increased 2.9% vs. 1Q26 — combined with the margin gains observed during the period, demonstrates an improvement in earnings quality. In 1H26, Net Revenue from Services totaled R$ 384.2 million, a decrease of 7.1% compared to 1H25. The year-over-year comparison remains impacted by changes in compounding operations, while the improvement in profitability reinforces the progress of the strategy adopted to adapt the business to the new contracting model, while the other Services segments, particularly Humania, continue to increase their contribution to the business unit. Gross Profit R$ thousand 2Q26 2Q25 Var.% 1H26 1H25 Var.% Gross Profit 483,917 422,451 14.5% 930,396 806,670 15.3% Gross Margin 16.6% 15.0% 1.6 p.p 16.2% 14.4% 1.8 p.p In 2Q26, Gross Profit totaled R$ 483.9 million, an increase of 14.5% compared to 2Q25. Gross Margin reached 16.6%, an expansion of 1.6 p.p. year -over-year and 0.8 p.p. compared to the previous quarter, representing the seventh consecutive quarter of year-over-year improvement. Excluding the effect of CMED, Gross Margin would have been 16.1%, compared to 14.6% in 2Q25. Performance reflects the continued implementation of profitability improvement initiatives across different business areas. All channels showed margin improvements compared to the previous year. In Hospitals and Clinics, the evolution of the mix, pricing a nd contract adjustments contributed to the improvement. In Retail, the price increases implemented at the beginning of the year supported margin recovery. Results were also benefited by the higher profitability of the compounding operation, with the prioritization of more profitable business lines, as well as the progress of other initiatives focused on operational efficiency and business profitability. It is worth noting that the annual price adjustment established by CMED in 2026 was the lowest in the past 20 years. The maximum authorized adjustments were 3.81%, 2.47% and 1.13% for medicines classified in Tiers 1, 2 and 3, respectively, below the percentages of 5.06%, 3.83% and 2.60% established in 2025. Considering that approximately 90% of the Company’s portfolio is classified in Tier 3 and the remaining 10% in Tier 2, the CMED adjustment, although contributing positively to the Company’s results, was lower than that observed in previous years due to the lower authorized adjustment percentages. In 1H26, Gross Profit totaled R$ 930.4 million, an increase of 15.3% compared to 1H25, with Gross Margin of 16.2%, an expansion of 1.8 p.p. Excluding the CMED effect, Gross Profit would have been R$ 916.4 million, an increase of 15.4% compared to 1H25, whi le Gross Margin also increased by 1.8 p.p., reaching 16.0%.
Page 8
Earning Release 2Q26 e 1H26 ▪ 7 Operating Expenses In 2Q26, Operating Expenses, excluding non -recurring items and depreciation and amortization, totaled R$ 278.8 million, an increase of 3.9% compared to 2Q25, broadly in line with the evolution of Net Revenue during the period. As a percentage of revenue, they remained practically stable at 9.6%, compared to 9.5% in 2Q25. Selling Expenses, ex-D&A, totaled R$ 99.2 million, an increase of 4.8%, in line with the growth in Gross Revenue during the period. General and Administrative Expenses, ex-D&A, totaled R$ 169.6 million, a decrease of 1.9% compared to 2Q25. Non-recurring Adjustments totaled a negative balance of R$ 6.5 million, resulting from the reversal of amounts recognized under the long-term compensation plan, considering the change in the Company’s management. In 1H26, Operating Expenses, excluding non -recurring items and depreciation and amortization, totaled R$ 529.0 million, an increase of 7.4% compared to 1H25, and represented 9.2% of Net Revenue, compared to 8.8% in the same period of the previous year. The increase during the first half mainly reflected higher personnel expenses, particularly provisions for variable compensation, in addition to higher Selling Expenses, in line with revenue growth. Depreciation and amortization expenses totaled R$ 75.6 million in 2Q26 and R$ 156.9 million in 1H26, increases of 9.5% and 14.7%, respectively, mainly reflecting additions to Property, Plant and Equipment and intangible assets, as well as new contracts and lease adjustments. 1-Amounts disclosed in Notes 12, 13 and 14 to the financial statements. R$ thousand 2Q26 2Q25 Var. % 1H26 1H25 Var.% Selling Expenses (ex-D&A) (99,240) (94,686) 4.8% (185,438) (179,676) 3.2% G&A Expenses (ex-D&A) (169,643) (172,931) -1.9% (339,605) (324,396) 4.7% Losses on impairment of assets (default) (7,721) (7,243) 6.6% (15,196) (14,415) 5.4% Other Income and (Expenses), net 4,590 6,938 -33.8% 14,586 6,511 124.0% Share of gain (loss) in non-consolidated investees (312) (413) -24.5% (522) (874) -40.3% D&A related to Admin. and Selling expenses (75,642) (69,062) 9.5% (156,852) (136,715) 14.7% Total Expenses (347,968) (337,397) 3.1% (683,027) (649,565) 5.2% % of Net Revenue -12.0% -12.0% 0.0 p.p -11.9% -11.6% -0.3 p.p (+/-) Non-Recurring Adjustments (6,471) 12,245 -152.9% (2,847) 20,309 -114.0% Total Expenses ex-NR Items and D&A (278,797) (268,335) 3.9% (529,022) (492,541) 7.4% % of Net Revenue -9.6% -9.5% 0.0 p.p -9.2% -8.8% -0.4 p.p Depreciation and Amortization (D&A) 2Q26 2Q25 Var.% 1H26 1H25 Var.% (1) D&A related to Adm. and Selling expenses (1 = a+b+c) (75,642) (69,062) 9.5% (156,852) (136,715) 14.7% Amortization of goodwill ¹ (a) (26,760) (28,794) -7.1% (56,003) (57,686) -2.9% Other (b) (48,888) (40,268) 21.4% (100,849) (79,029) 27.6% D&A related to Selling expenses (c) - - N/A - - N/A (2) D&A in Costs (11,564) (11,489) 0.7% (23,457) (23,287) 0.7% Total D&A = 1+2 (87,206) (80,551) 8.3% (180,309) (160,002) 12.7%
Page 9
Earning Release 2Q26 e 1H26 ▪ 8 EBITDA and Adjusted EBITDA 1 - Non-recurring events detailed at the end of this section. In 2Q26, Adjusted EBITDA reached R$ 216.7 million, an increase of 21.8% compared to 2Q25, with an Adjusted EBITDA Margin of 7.4%, an expansion of 1.1 p.p. year-over-year. Excluding the effect of CMED in the comparable periods, Adjusted EBITDA Margin was 7.0%, an increase of 1.1 p.p. compared to 2Q25. Performance mainly reflects the expansion of Gross Margin, combined with operating expenses remaining relatively stable as a percentage of Net Revenue. In 1H26, Adjusted EBITDA totaled R$ 424.8 million, an increase of 25.9% compared to 1H25, with an Adjusted EBITDA Margin of 7.4%, an expansion of 1.4 p.p. Excluding the effect of CMED, the margin was 7.2%, also 1.4 p.p. higher than that recorded in 1H25. Financial Result In 2Q26, Net Financial Result was negative R$ 182.3 million, compared to a negative result of R$ 157.7 million in 2Q25. The variation was mainly due to the gain associated with the repurchase of debentures recognized in the prior period, in addition to the reduction in Financial Income, impacted by the lower average cash balance. Financial Expenses totaled R$ 201.4 million, a decrease of 10.4% year-over-year, mainly reflecting lower interest expenses on loans, financing and debentures, as well as lower monetary adjustment expenses. In 1H26, Net Financial Result was negative R$ 355.3 million, compared to a negative R$ 259.1 million in 1H25, broadly reflecting the same factors observed during the quarter. EBITDA (R$ thousand) 2Q26 2Q25 Var.% 1H26 1H25 Var.% Net Income / (Loss) (34,652) (71,358) -51.4% (91,660) (130,292) -29.6% Income Tax and Social Contribution (11,721) (1,262) 828.8% (16,232) 28,271 N/A Financial Result 182,322 157,674 15.6% 355,261 259,125 37.1% Depreciation and Amortization 87,206 80,551 8.3% 180,308 160,002 12.7% EBITDA 223,155 165,605 34.8% 427,678 317,106 34.9% EBITDA Margin 7.7% 5.9% 1.8 p.p 7.4% 5.7% 1.8 p.p (-) Adjustments¹ (6,471) 12,245 -152.9% (2,847) 20,309 -114.0% Adjusted EBITDA 216,684 177,850 21.8% 424,830 337,415 25.9% Adjusted EBITDA Margin 7.4% 6.3% 1.1 p.p 7.4% 6.0% 1.4 p.p (-) Adjustments 2Q26 2Q25 Var.% 1H26 1H25 Var.% M&A Expenses 558 4,516 -87.6% 1,190 5,648 -78.9% Stock Options (9,527) 775 -1328.9% (8,985) 1,818 -594.3% Escrow account 541 236 129.3% 649 3,403 -80.9% Strategic Projects / Integration 1,956 5,282 -63.0% 4,300 7,325 -41.3% ICMS – DIFAL Litigation - - N/A - 1,574 N/A Rio Grande do Sul - 1,379 N/A - 1,379 N/A Other - 57 N/A - (839) N/A Total (6,471) 12,245 -152.9% (2,847) 20,309 -114.0%
Page 10
Earning Release 2Q26 e 1H26 ▪ 9 Net Income (Loss) and Adjusted Net Income (Loss) 1 - Net effect of Income Tax and Social Contribution at a 34% tax rate. 2 - Deferred tax assets not recognized on definitive inventory provision write-offs in 4Q24, as disclosed in Note 20 to the 1Q25 financial statements. In 2Q26, the Company reported an Adjusted Net Loss of R$ 21.3 million, a decrease of 52.0% compared to the loss of R$ 44.3 million in 2Q25. Adjusted Net Margin was negative 0.7%, an improvement of 0.8 p.p. year-over-year. Performance mainly reflects the improvement in operating performance, partially offset by the deterioration in Net Financial Result. In 1H26, Adjusted Net Loss totaled R$ 56.6 million, a decrease of 13.2% compared to 1H25, with Adjusted Net Margin of negative 1.0%, an improvement of 0.2 p.p. year-over-year. R$ thousand 2Q26 2Q25 Var.% 1H26 1H25 Var.% Financial Income 19,092 67,086 -71.5% 46,295 144,263 -67.9% Income from Financial Investments 5,208 12,715 -59.0% 13,312 35,303 -62.3% Interest Income 2,758 4,648 -40.7% 5,449 7,674 -29.0% Gain on Derivatives - - N/A - - N/A Foreign Exchange Variation 3,030 8,592 -64.7% 9,017 23,563 -61.7% Gain on Debenture Repurchase - 25,297 -100.0% - 58,710 -100.0% Monetary Adjustment 8,434 14,878 -43.3% 16,163 16,748 -3.5% Other Financial Income (338) 956 -135.4% 2,354 2,265 3.9% Financial Expenses (201,414) (224,760) -10.4% (401,556) (403,388) -0.5% Interest on Loans, Financing and Debentures (124,700) (134,559) -7.3% (254,771) (260,975) -2.4% Banking Expenses (2,414) (2,853) -15.4% (4,978) (4,493) 10.8% Discounts Granted (983) (102) 863.7% (1,981) (1,917) 3.3% Loss on Derivatives (2,412) (7,969) -69.7% (8,599) (17,523) -50.9% Foreign Exchange Variation (743) (2,810) -73.6% (962) (3,125) -69.2% Monetary Adjustment (32,533) (50,278) -35.3% (54,982) (71,311) -22.9% Financial Transactions Tax – IOF (824) (1,237) -33.4% (2,139) (1,998) 7.1% Lease Interest (11,563) (12,163) -4.9% (30,251) (21,827) 38.6% Other Financial Expenses (25,242) (12,789) 97.4% (42,893) (20,219) 112.1% Financial Result (182,322) (157,674) 15.6% (355,261) (259,125) 37.1% R$ thousand 2Q26 2Q25 Var.% 1H26 1H25 Var.% Net Income (Loss) (34,652) (71,358) -51.4% (91,660) (130,292) -29.7% EBITDA Non-Recurring Items¹ (4,271) 8,082 -152.9% (1,879) 13,404 -114.0% Amortization of acquisition-related fair value adj.¹ 17,658 19,004 -7.1% 36,958 38,073 -2.9% Unrecognized Deferred Tax Assets² - - N/A - 13,658 N/A Adjusted Net Income (Loss) (21,265) (44,272) -52.0% (56,581) (65,157) -13.2% Adjusted Net Margin -0.7% -1.6% 0.8 p.p -1.0% -1.2% 0.2 p.p
Page 11
Earning Release 2Q26 e 1H26 ▪ 10 Cash Flow Indicators In 2Q26, Cash Flow from Operating Activities totaled R$ 161.5 million, a decrease of 23.8% compared to 2Q25, but an increase of 23.2% year -to-date, reaching R$ 243.6 million at the end of the period. During the quarter, R$ 250.3 million in receivables were advanced. In the first half, Cash Flow from Operating Activities increased 23.2%, totaling R$ 243.6 million. Working capital performance benefited from Accounts Receivable, as a result of efforts to reduce customer payment terms, while inventory financing deteriorated due to the product and supplier mix. Free Cash Flow increased 36.6% compared to 1H25, reaching R$ 170.3 million, mainly reflecting higher operating cash generation, while investments (CAPEX) remained broadly stable at R$ 73.3 million. Cash Conversion Cycle In 2Q26, the Cash Conversion Cycle ended the period at 53 days, a reduction of 4 days compared to 2Q25 and 1 day compared to 1Q26. The improvement reflects the continued implementation of working capital management initiatives, with a reduction in the aver age customer collection period and inventory levels on a sequential basis, partially offset by payments to suppliers related to purchases made at the beginning of the year. R$ thousand 2Q26 2Q25 Var. % 1H26 1H25 Var.% EBITDA 223,155 165,605 34.8% 427,678 317,106 34.9% Non-cash Adjustments 724 5,886 -87.7% 20,286 26,539 -23.6% IFRS 16 – Leases (30,625) (27,433) 11.6% (61,291) (55,554) 10.3% Working Capital Variation (30,018) 72,906 -141.2% (138,205) (81,455) 69.7% Accounts Receivable 90,617 104,460 -13.3% 196,424 94,169 108.6% Inventories 14,898 176,275 -91.5% (146,029) 17,399 -939.3% Suppliers (100,731) (221,590) -54.5% (115,395) (208,209) -44.6% Taxes (26,552) (6,741) 293.9% (53,954) (18,113) 197.9% Labor and Social Security Obligations (5,317) 19,794 -126.9% (6,707) 23,660 -128.3% Other Operating Effects (2,933) 708 -514.4% (12,544) 9,639 -230.1% Income Tax and Social Contribution Paid (1,732) (4,996) -65.3% (4,874) (8,850) -44.9% Cash Flow from Operating Activities (1) 161,504 211,968 -23.8% 243,594 197,786 23.2% Cash Flow from Investing Activities (CAPEX) (2) (36,736) (35,173) 4.4% (73,321) (73,143) 0.2% Free Cash Flow (1+2) 124,768 176,795 -29.4% 170,273 124,643 36.6% Financial Result (127,666) (108,981) 17.1% (288,229) (222,884) 29.3% Financial Investments (2,179) (750) 190.5% 21,032 562,976 -96.3% Funding - (13,709) N/A - (13,709) N/A Amortizations (68,985) (106,116) -35.0% (77,812) (153,729) -49.4% M&A Payments (9,905) (19,732) -49.8% (11,670) (45,626) -74.4% Intercompany / Other (84) (72) 16.7% (167) (6,456) -97.4% Cash Flow from Financing Activities (208,819) (249,360) -16.3% (356,846) 120,572 -396.0% Net Change in Cash and Cash Equivalents (84,051) (72,565) 15.8% (186,573) 245,215 -176.1%
Page 12
Earning Release 2Q26 e 1H26 ▪ 11 Excluding the effect of receivables advances, the Cash Conversion Cycle would have been 60 days, compared to 64 days in 2Q25 and 61 days in 1Q26. The ratio of Working Capital to Net Revenue ended the quarter at 16.5%, compared to 17.5% in 2Q25 and 16.6% in 1Q26. 1 - See appendix for details on Working Capital. Net Debt As of June 30, 2026, the Company’s gross debt amounted to R$ 3,369.2 million, a reduction of R$ 73.0 million compared to the end of 4Q25 and R$ 300.4 million compared to the end of 2Q25. Viveo reported Net Debt of R$ 2,918.2 million at the end of 2Q26, an increase of R$ 134.6 million compared to the end of 4Q25 and R$ 61.1 million compared to the end of 2Q25. At the end of 2Q26, 93.0% of the Company’s debt was due in the long term, with an average debt maturity of 7.3 years. Of total debt, 98.4% was contracted in local currency, while the portion denominated in foreign currency was fully hedged against the Brazilian Real through financial instruments. In 2Q26, the Company’s average cost of debt was CDI +1.54%, compared to CDI +1.54% in 4Q25 and CDI +1.55% in 2Q25. In June 2026, Viveo completed the renegotiation of the terms of its debentures, including the revision of the covenant curve (Net Debt/EBITDA), the extension of the debt amortization schedule and the maturity of the debt. As part of the transaction, custom ary obligations for this type of negotiation were assumed, with no material impact on the cost of debt. The renegotiation strengthens the Company’s balance sheet, relieving pressure from short-term principal payments and providing greater security for the execution of its long-term strategy. For covenant purposes, the new ratio is calculated as Net Debt from loans and debentures, including taxes payable under installment plans, divided by Adjusted EBITDA, including cash lease payments. The new ratios used for covenant testing are: • 4.75x as of June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027; • 4.50x as of June 30, 2027, September 30, 2027, December 31, 2027 and March 31, 2028; • 4.00x as of June 30, 2028, September 30, 2028, December 31, 2028 and March 31, 2029; • 3.75x as of June 30, 2029, September 30, 2029, December 31, 2029 and March 31, 2030; and Cash Conversion Cycle (days) 2Q25 3Q25 4Q25 1Q26 2Q26 Accounts Receivable Cycle 58 56 54 58 54 Accounts Rec. Cycle ex-Rec. Anticipation 65 63 61 65 61 Accounts Payable Cycle 64 64 65 73 68 Inventory Days 63 63 56 68 67 Cash Conversion Cycle 57 55 44 54 53 Cash Conversion Cycle ex-Rec. Anticipation 64 62 51 61 60 Working Capital¹ / Net Revenue (%) 17.5% 17.2% 15.9% 16.6% 16.5%
Page 13
Earning Release 2Q26 e 1H26 ▪ 12 • 3.50x from June 30, 2030 until the maturity of the debentures. Additionally, the acquisitions of companies have generated future payment obligations, which may materialize in full or in part. Considering the outstanding M&A payable balance, the Company’s pro forma leverage ratio is 4.65x. 1 - For further information, please refer to Note 4.3 (f) to the financial statements. 2 - In the calculation of Net Debt/Adjusted EBITDA, Taxes Payable under Installment Plans were considered as Net Debt, in order to align with the Company’s covenant calculation. 3- As of April 2026, there is no longer any impact from the pro forma adjustment to EBITDA related to the acquisition of DFLOG in the calculation of EBITDA. 4 - For purposes of calculating EBITDA for covenant purposes, the deduction of lease payments based on the cash flow for the last 12 months is considered. Capital Increase On June 26, 2026, Viveo’s Board of Directors approved a capital increase, within the limits of the authorized capital, in an amount of up to R$ 869.8 million, through the issuance of up to 966,401,192 new common shares, at a price of R$ 0.90 per share. The shares may be paid in ca sh in Brazilian currency or through the capitalization of credits held against the Company. Partial approval of the capital increase will be permitted, provided that the minimum subscription amount of R$ 427.0 million is reached, which is subject to a subscription commitment by investment vehicles managed by DNA Capital. The transaction’s main objectives are to reduce Net Debt, ensure greater financial balance and improve the Company’s capital structure. Shareholders holding shares as of July 1, 2026 were granted preemptive rights to subscribe for the new shares, in proportion to their respective holdings, with the exercise period extending through August 17, 2026. Following the end of this period, the applicable procedures for the subscription of any remaining Loans and Financing (R$ million) 06/30/2026 03/31/2026 12/31/2025 09/30/2025 06/30/2025 Var. 06/30/2026 x 12/31/2025 Var. 06/30/2026 x 06/30/2025 Cash and Cash Equivalents and Financial Investments 451.0 532.8 658.6 806.0 812.4 -31.5% -44.5% Loans and Financing (289.4) (358.4) (359.2) (422.6) (355.2) -19.4% -18.5% Debentures (3,075.7) (3,050.5) (3,081.2) (3,184.0) (3,309,6) -0.2% -7.1% Derivative Instruments¹ (4.1) (7.1) (1.8) (8.4) (4.8) 122.2% -15.7% Net Debt (2,918.2) (2,883.2) (2,783.7) (2,809.1) (2,857.2) 4.8% 2.1% Taxes Payable in Installments (43.0) (44.4) (45.9) (49.0) (44.2) -6.3% -2.7% Net Debt/Adjusted EBITDA²˒³ 3.73x 3.88x 3.97x 4.17x 4.33x - - Leverage Ratio²˒⁴ (covenants) 4.39x 4.58x 4.71x 5.00x 5.19x - - 1.113 937 972 797 71 76 70 70 67 263 187 117 316 547 553 547 933 677 2026 2027 2028 2029 2030 2031 2032 2033 2034 Debt Amortization Schedule 1Q26 Outlook Post-Restructuring
Page 14
Earning Release 2Q26 e 1H26 ▪ 13 shares and the subsequent approval of the capital increase by the Board of Directors will be carried out. As these steps take place after June 30, 2026 and the transaction had not yet been completed as of the quarter-end, its effects are not reflected in the 2Q26 financial information. Based on the June 30, 2026 figures and considering the Minimum and Maximum Capital Increase scenarios, the Company’s pro forma leverage ratio would decrease from 3.73x to 3.19x under the minimum subscription scenario and to 2.64x under the full subscription scenario. These estimate s demonstrate the transaction’s significant contribution to the deleveraging process and to strengthening Viveo’s capital structure. Capital Markets At the end of 2Q26, the Company’s shares closed the period at R$ 0.72, with a market capitalization of R$ 232.4 million, a decrease of 41.9% compared to the end of 1Q26. During the period, the average number of trades increased 45.4% to 2.41 million, while the average daily trading volume increased 21.1%, reaching R$ 2.8 million. At the end of the period, Viveo’s shares were included in the portfolios of the following B3 indices: IGCX, IGNM and ITAG, reinforcing the Company’s commitment to the corporate governance principles of the Novo Mercado. 1 - Closing price adjusted for dividends and other distributions. Return on Invested Capital (ROIC) 1 - Considers the same adjustments applied to EBITDA. 2 - Includes software within intangible assets. VVEO31 Market Capitalization 2Q26 vs. 1Q26 Average No. of Transactions Average Financial Volume 03/31/2026 R$ 1.24 R$ 400.3 million 1.66 million R$ 2,324,472 06/30/2026 R$ 0.72 R$ 232.4 million 2.41 million R$ 2,814,774 Variação -41.9% -41.9% 45.4% 21.1% (R$ million) 06/30/2025 09/30/2025 12/31/2025 03/31/2026 06/30/2026 (a) EBIT (809,438) (351,079) 531,665 571,034 621,917 (b) EBIT Adjustments¹ and Amortization of acquisition- related fair value adjustments 1,258,858 819,988 (44,566) (48,625) (69,405) (c) Adjusted EBIT (a+b) 449,420 468,909 487,099 522,409 552,512 (d) Income Tax and Social Contribution (34%) (152,803) (159,429) (165,614) (177,619) (187,854) (1) NOPAT (c+d) 296,617 309,480 321,485 344,790 364,658 (e) Working Capital 2,008,131 1,954,297 1,838,080 1,931,344 1,935,839 Property, Plant and Equipment(f) 510,573 493,728 485,230 471,082 456,354 Intangible Assets² (g) 306,314 317,342 324,901 330,596 334,582 (h) Fixed Assets (f + g) 816,887 811,070 810,131 801,678 790,936 (2) Invested Capital (e+h) 2,825,018 2,765,367 2,648,211 2,733,022 2,726,775 ROIC (1/2) 10.5% 11.2% 12.1% 12.6% 13.4%
Page 15
Earning Release 2Q26 e 1H26 ▪ 14 APPENDICES Consolidated Statement of Income Consolidated Statement of Financial Position (R$ thousand) ASSETS 06/30/26 12/31/25 Var. Cash and Cash Equivalents 387,070 573,643 -32.5% Financial Investments 63,888 84,920 -24.8% Trade Accounts Receivable 1,798,522 2,007,835 -10.4% Inventories 1,796,255 1,656,826 8.4% Recoverable Taxes 294,920 203,807 44.7% Derivative Financial Instruments - - N/A Other Assets 59,044 57,224 3.2% Recoverable Income Tax and Social Contribution 72,639 67,213 8.1% Related Party Transactions 2,326 2,159 7.7% Total Current Assets 4,474,664 4,653,627 -3.8% Trade Accounts Receivable 12,946 17,771 -27.2% R$ mil 2Q26 2Q25 Var. % 1H26 1H25 Var.% Net Revenue 2,910,169 2,815,509 3.4% 5,742,089 5,600,402 2.5% Cost of Goods and Services Sold (2,426,252) (2,393,058) 1.4% (4,811,693) (4,793,733) 0.4% Gross Profit 483,917 422,451 14.5% 930,396 806,669 15.3% Gross Margin 16.6% 15.0% 1.6 p.p 16.2% 14.4% 1.8 p.p Operating Expenses (347,968) (337,397) 3.1% (683,027) (649,565) 5.2% Selling Expenses (99,240) (94,686) 4.8% (185,438) (179,676) 3.2% General and Administrative Expenses (245,285) (241,993) 1.4% (496,457) (461,111) 7.7% Allowance for Doubtful Accounts (ADA) (7,721) (7,243) 6.6% (15,196) (14,415) 5.4% Other Income 7,589 16,450 -53.9% 19,447 21,211 -8.3% Other Expenses (2,999) (9,512) -68.5% (4,861) (14,700) -66.9% Share of Gain (Loss) in Non- Consolidated Investees (312) (413) -24.5% (522) (874) -40.3% Financial Result (182,322) (157,674) 15.6% (355,261) (259,125) 37.1% Financial Income 19,092 67,086 -71.5% 46,295 144,263 -67.9% Financial Expenses 201,414 (224,760) -10.4% (401,556) (403,388) -0.5% EBT (46,373) (72,620) -36.1% (107,892) (102,020) 5.8% Income Tax and Social Contribution 11,721 1,262 828.8% 16,232 (28,271) -157.4% Current Income Tax and Social Contribution 3,721 (3,968) -193.8% 5,680 (10,911) -152.1% Deferred Income Tax and Social Contribution 8,000 5,230 53.0% 10,552 (17,360) -160.8% Net Income (34,652) (71,358) -51.4% (91,660) (130,292) -29.7%
Page 16
Earning Release 2Q26 e 1H26 ▪ 15 Recoverable Taxes 124,348 127,227 -2.3% Judicial Deposits 57,634 53,879 7.0% Deferred Tax Assets 713,781 695,776 2.6% Other Assets 28,406 26,898 5.6% Investments - 180 N/A Property, Plant and Equipment 456,354 485,230 -6.0% Intangible Assets 2,501,251 2,547,320 -1.8% Related Party Transactions - - N/A Right-of-Use Assets 390,719 374,077 4.4% Derivative Financial Instruments - 1,773 N/A Total Non-Current Assets 4,285,439 4,330,131 -1.0% Total Assets 8,760,103 8,983,758 -2.5% LIABILITIES 06/30/26 12/31/25 Var. Suppliers 1,809,249 1,924,445 -6.0% Suppliers – Reverse Factoring 24,168 24,367 -0.8% Taxes Payable 87,009 64,888 34.1% Loans and Financing 104,586 146,605 -28.7% Debentures 130,053 851,316 -84.7% Salaries and Social Obligations Payable 131,272 112,767 16.4% Taxes Payable in Installments 10,418 11,263 -7.5% Income Tax and Social Contribution Payable 203 2,036 -90.0% Customer Advances 7,414 4,355 70.2% Dividends Payable - - N/A Lease Liabilities 95,360 98,421 -3.1% Provision for Tax, Civil and Labor Risks - - N/A Derivative Financial Instruments 4,067 3,603 12.9% Tax Lawsuit Transfer Obligation - - N/A Provision for Investment Losses - - N/A Obligations Related to Acquisition of Investments 90,558 137,439 -34.1% Obligations with Former Subsidiary 12,911 17,625 -26.7% Other Liabilities 90,881 100,393 -9.5% Total Current Liabilities 2,598,149 3,499,523 -25.8% Loans and Financing 184,840 212,620 -13.1% Debentures 2,945,631 2,229,845 32.1% Obligations Related to Acquisition of Investments 641,334 570,802 12.4% Taxes Payable - - N/A Taxes Payable in Installments 32,594 34,638 -5.9% Deferred Taxes - - N/A Provision for Tax, Civil and Labor Risks 148,563 142,267 4.4% Provision for Investment Losses 1,011 552 83.2% Lease Liabilities 362,215 331,773 9.2% Derivative Financial Instruments - - N/A
Page 17
Earning Release 2Q26 e 1H26 ▪ 16 Obligations with Former Subsidiaries 14,461 14,132 2.3% Other Liabilities 8,751 10,517 -16.8% Total Non-Current Liabilities 4,339,400 3,547,146 22.3% Share Capital 2,549,392 2,549,392 0.0% Capital Reserve (284,102) (275,117) 3.3% Retained Earnings Reserve (442,736) (337,186) 31.3% Total Shareholders’ Equity 1,822,554 1,937,089 -5.9% Total Liabilities and Shareholders’ Equity 8,760,103 8,983,758 -2.5% Statement of Cash Flows (R$ thousand) Statement of Cash Flows 2Q26 2Q25 Var% 1H26 1H25 Var.% Cash Flow from Operating Activities 64,463 130,420 -50.6% 16,656 24,135 -31.0% Cash Generated from Operations 202,044 172,829 16.9% 417,088 360,260 15.8% Net Income (Loss) (34,652) (71,358) -51.4% (91,660) (130,292) -29.6% Depreciation and Amortization 87,206 80,551 8.3% 180,309 160,002 12.7% Write-off of Assets and Gain/Loss on Disposal of Property, Plant and Equipment (1,476) (106) 1292% (1,666) 289 -676% Impairment Losses on Trade Accounts Receivable 7,721 7,243 6.6% 15,196 14,415 5.4% Monetary Adjustment on Acquisition of Investments 29,016 21,925 32.3% 47,259 41,532 13.8% Interest, Monetary and Foreign Exchange Variations, net 117,496 142,252 -17.4% 238,276 253,568 -6.0% Interest on Lease Liabilities 11,563 12,163 -4.9% 30,251 21,827 38.6% Provision (Reversal) for Contingencies 5,114 (3,889) -231.5% 17,716 8,977 97.3% Derivative Financial Instruments 2,412 7,969 -69.7% 8,599 17,523 -50.9% Share of Profit (Loss) of Subsidiaries 312 413 -24.5% 522 874 -40.3% Income Tax (11,721) (1,262) 828.8% (16,232) 28,271 -157.4% Gain from Tax Lawsuits (25) (14) 78.6% (25) (769) -96.7% Recognized Granted Options (9,527) 775 - 1329.3% (8,985) 1,818 -594.2% Fair Value Adjustment of Obligations Related to Acquisition of Investments (1,428) (2,467) -42.1% (2,588) (2,996) -13.6% Losses from Discontinued Investments 33 3,931 -99.2% 117 3,931 -97.0% Gain on Debenture Repurchase - (25,297) N/A - (58,710) N/A Changes in Assets and Liabilities (30,018) 72,906 -141.2% (138,205) (87,776) 57.5% Trade Accounts Receivable 98,471 107,148 -8.1% 193,365 100,703 92.0% Inventories 14,898 176,275 -91.5% (146,029) 17,399 -939.3% Recoverable Taxes (31,440) (3,625) 767.3% (81,739) (15,465) 428.5% Judicial Deposits (2,234) (2,035) 9.8% (5,072) 11,149 -145.5% Other Assets 5,753 3,148 82.8% 3,781 17,899 -78.9% Suppliers (100,418) (218,666) -54.1% (115,196) (191,165) -39.7% Social and Labor Obligations (5,317) 19,794 -126.9% (6,707) 23,660 -128.3% Tax Obligations 4,888 (3,116) -256.9% 27,786 (2,648) - 1149.3% Customer Advances (7,854) (2,688) 192.2% 3,059 (6,534) -146.8%
Page 18
Earning Release 2Q26 e 1H26 ▪ 17 Other Liabilities (6,452) (405) 1493.3% (11,254) (25,730) -56.3% Suppliers – Reverse Factoring (313) (2,924) -89.3% (199) (17,044) -98.8% Other (107,563) (115,315) -6.7% (262,227) (248,349) 5.6% Interest Paid on Loans and Debentures (105,831) (110,319) -4.1% (257,353) (239,499) 7.5% Income Tax and Social Contribution Paid (1,732) (4,996) -65.3% (4,874) (8,850) -44.9% Net Cash from Investing Activities (38,915) (50,132) -22.4% (52,289) 475,624 -111.0% Acquisition of investments, net of cash - (14,209) N/A - (14,209) N/A Acquisition of Property, Plant and Equipment (5,742) (8,296) -30.8% (13,156) (15,213) -13.5% Acquisition of Intangible Assets (30,994) (26,877) 15.3% (60,165) (57,930) 3.9% Financial Investments (2,179) (750) 190.5% 21,032 562,976 -96.3% Net Cash from Financing Activities (109,599) (152,853) -28.3% (150,940) (254,544) -40.7% Issuance of debentures - (13,709) N/A - (13,709) N/A Repayment of Loans and Financing (60,309) (57,334) 5.2% (65,694) (62,719) 4.7% Lease Liability Payments (30,625) (27,433) 11.6% (61,291) (55,554) 10.3% Loans granted to (received from) subsidiaries/investees (84) (72) 16.7% (167) (135) 23.7% Derivative Settlement Payments (5,405) (4,061) 33.1% (6,362) (4,656) 36.6% Debenture Repurchase - (36,825) N/A - (78,458) N/A Payments for Acquisition of Investments (9,905) (5,523) 79.3% (11,670) (31,417) -62.9% Payments of Taxes Payable in Installments (3,271) (7,896) -58.6% (5,756) (7,896) -27.1% Net Change in Cash and Cash Equivalents (84,051) (72,565) 15.8% (186,573) 245,215 176.1% Cash and Cash Equivalents at the Beginning of the Period 471,121 861,446 -45.3% 573,643 543,666 5.5% Cash and Cash Equivalents at the End of the Period 387,070 788,881 -50.9% 387,070 788,881 -50.9% Working Capital R$ thousand 06/30/2025 09/30/2025 12/31/2025 03/31/2026 06/30/2026 Trade Accounts Receivable¹ 1,994,016 1,908,979 2,025,606 1,923,237 1,811,468 Inventories 1,683,363 1,682,484 1,656,826 1,814,453 1,796,255 Recoverable Taxes¹ 260,570 284,248 331,034 384,846 419,268 Other Assets 75,188 76,731 57,224 58,127 59,044 Assets 4,013,137 3,952,442 4,070,690 4,180,663 4,086,035 R$ thousand 06/30/2025 09/30/2025 12/31/2025 03/31/2026 06/30/2026 Suppliers 1,652,772 1,680,505 1,924,445 1,909,667 1,809,249 Suppliers – Reverse Factoring 45,739 27,336 24,367 24,481 24,168 Salaries and Social Obligations Payable 115,585 119,529 112,767 120,245 131,272 Taxes Payable¹ 92,475 69,163 64,888 84,176 87,009 Customer Advances 12,347 9,003 4,355 15,268 7,414 Income Tax and Social Contribution Payable 1,578 1,871 2,036 432 203 Other Liabilities 91,042 90,738 100,393 95,050 90,881 Liabilities 2,005,006 1,998,145 2,233,251 2,249,319 2,150,196 Net Working Capital 2,008,131 1,954,297 1,837,439 1,931,344 1,935,839
Page 19
Earning Release 2Q26 e 1H26 ▪ 18 1 - Includes Current and Non-Current Debt Amortization Schedule – Post-Restructuring Schedule¹ (R$ thousand) Debt Amortization M&As Payable Taxes Payable in Installments Total 2026 (CP) 187,365 69,947 5,938 263,250 2027 (CP) 47,274 20,611 4,480 72,365 2027 25,050 85,422 3,681 114,153 2028 21,042 89,303 7,112 117,457 2029 234,688 74,515 6,499 315,702 2030 466,404 77,247 3,572 547,224 2031 466,404 83,106 3,143 552,654 2032 466,404 77,247 3,143 546,795 2033 852,598 77,247 3,143 932,988 2034 597,881 77,247 2,301 677,426 Total 3,365,110 731,892 43,012 4,140,014 1 - Does not include derivative settlement payments. Net Revenue 11,484,006 11,370,859 11,566,926 11,613,953 11,708,613 Working Capital / Net Revenue 17.5% 17.2% 15.9% 16.6% 16.5%
Page 20
Earning Release 2Q26 e 1H26 ▪ 19 Disclaimer This document may contain statements regarding the Company’s future business perspectives, estimates of operating and financial results, growth prospects and other forward -looking statements. Statements contained herein that refer to forward-looking perspectives include, but are not limited to, expressions such as “anticipate,” “believe,” “estimate,” “expect,” “project,” “plan,” “forecast,” “target,” “aim,” “seek,” as well as variations of such terms and similar expressions intended to identify forward-looking statements. Such statements involve various factors, risks and uncertainties, whether known or unknown, which may cause actual results to differ materially from those expressed or implied in this document and do not constitute any guarantee of future performance by the Company. All statements contained in this document are based on information and data available as of the date on which they were published. The Company undertakes no obligation to revise or update them considering new information or future events. Readers/investors are solely and exclusively responsible for any investment decisions, business decisions or actions taken based on the information contained in this document. Readers/investors should not rely exclusively on the information contained herein when making decisions regarding the trading of securities issued by the Company. For more detailed information, please refer to our Financial Statements, Reference Form and other relevant information available on the Company’s Investor Relation s website: https://ri.viveo.com.br/en/. This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.